{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-105038","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.000472+00:00","generated_at":"2026-06-10T07:11:09.169089+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Structure Therapeutics raises ~$300M in private placement for GLP-1 pipeline","bullets":["Sold 21.6M ordinary shares and 2.4M non-voting ordinary shares at $12.49/share (~$37.47/ADS) for ~$300M gross proceeds.","Proceeds to fund oral GLP-1R agonist GSBR-1290, next-gen GLP-1/GIPR combo, oral amylin agonist, and operations through at least 2026.","Closing expected on or about Oct 3, 2023; Jefferies and Leerink act as placement agents with 6% fee.","Registration statement to be filed within 45 days of closing to register resale of shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-105038","json":"https://secwatch.observer/filing/0001104659-23-105038.json","markdown":"https://secwatch.observer/filing/0001104659-23-105038.md","text":"https://secwatch.observer/filing/0001104659-23-105038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923105038/0001104659-23-105038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923105038/tm2327162d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:11:09.169089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"daedb9f088e404f69c79f7ae13f373c2aac9d603","claim":"Structure Therapeutics Inc. entered into Purchase Agreement with certain institutional investors valued at aggregate gross proceeds of approximately $300 million (effective 2023-09-29).","evidence_excerpt":"On September 29, 2023, Structure Therapeutics Inc. (the “Company”) entered into a share purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923105038/0001104659-23-105038-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"aggregate gross proceeds of approximately $300 million"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}